Clinical Trials
12 trialsNCT00788125 2023-07-14
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
Phase 1/2 Terminated
NCT05751733 2023-03-02
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
Xiangya Hospital of Central South University
Phase NA Recruiting
NCT03041701 2022-04-14
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00869401 2020-02-13
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT00892177 2019-10-21
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00423735 2019-07-24
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00568750 2019-06-17
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
Swiss Cancer Institute
Phase 2 Completed
NCT00464620 2018-11-23
Trial of Dasatinib in Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00895960 2018-11-08
Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01643278 2017-01-10
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
National Cancer Institute (NCI)
Phase 1 Completed
NCT02776878 2016-05-18
A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
Peking University Cancer Hospital & Institute
Phase NA Unknown
NCT00609999 2014-07-16
Ph I Dasatinib + Erlotinib in Recurrent MG
Duke University
Phase 1 Completed